Predictive biomarker of Neuromyelitis Optica spectrum disorders relapse
Predicting risk of relapse in patients with Neuromyelitis Optica spectrum disorders.
In patients with NMOSD, disability accumulates primarily through relapses. Researchers at Oxford have identified AQP4-IgM and AQP4-IgG subclasses as autoantibodies linked to an increased risk of relapse. This can be used as a biomarker for determining treatment or recruiting for clinical trials.
Applications: Disease monitoring, treatment response, autoimmune encephalitis
| Features | Benefits |
|---|---|
| Detects Aquaporin-4 (AQP4)-IgM or specific AQP4-IgG subclasses indicative of relapse | Only biomarker available for identification of relapse in patients with NMOSD |
| AQP4-IgM and AQP4-IgG subclasses had a strong odds ratio for an association with relapses (~6), including a high negative predictive value (~9) | Accurate identification of those at risk of relapse for use by: Routine clinical care, Healthcare providers to decide on provision of expensive/toxic therapies, Clinical trials to help define endpoints, with relapses often the primary endpoint for NMOSD |
| Serum-based test | Minimally invasive |
| Assay detects treatment associated reductions in antibodies that cause relapses | Easily obtained and stored for analysis |
| Can be used as a biomarker for treatment response, or in clinical trials to evaluate efficacy of therapeutic |
Patented and Available For
- Co-development
- Consulting
- Licensing